1.68  0.02 (1.2%)		10-14 16:00
Open: 1.61 High: 1.72 Volume: 637,289		Pre. Close: 1.66 Low: 1.6 Market Cap: 33(M)

Short term
Mid term
Targets	6-month :	2.57	1-year :	3.03
Resists	First :	2.2	Second :	2.59
Pivot price	2.06
Supports	First :	1.57	Second :	1.3
MAs	MA(5) :	1.9	MA(20) :	2.12
	MA(100) :	2.48	MA(250) :	3.45
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	9.6	D(3) :	24.8
RSI	RSI(14): 26.6
52-week	High :	10.53	Low :	1.11

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ANVS ] has closed above bottom band by 4.1%. Bollinger Bands are 10.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.72 - 1.73	1.73 - 1.74
Low:	1.58 - 1.59	1.59 - 1.6
Close:	1.66 - 1.68	1.68 - 1.7

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Fri, 10 Oct 2025
Annovis Bio, Inc. Announces $6 Million Registered Direct Offering of Common Stock - Quiver Quantitative

Fri, 10 Oct 2025
Annovis Announces $6 Million Registered Direct Offering of Common Stock - Stock Titan

Fri, 10 Oct 2025
Annovis Announces $6 Million Registered Direct Offering of Common Stock - TradingView

Thu, 09 Oct 2025
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer’s Patients - citybuzz

Thu, 09 Oct 2025
Annovis Bio Reports Promising Biomarker Results for Buntanetap in Alzheimer’s Disease Treatment - Quiver Quantitative

Thu, 09 Oct 2025
Annovis Announces Novel Biomarker Data in Alzheimer’s - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Biotechnology
Shares Out	19 (M)
Shares Float	16 (M)
Held by Insiders	14.8 (%)
Held by Institutions	14.5 (%)
Shares Short	1,400 (K)
Shares Short P.Month	1,710 (K)

EPS	-2.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.93
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-111.7 %
Return on Equity (ttm)	-365.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-25 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-0.81
PEG Ratio	0
Price to Book value	1.78
Price to Sales	0
Price to Cash Flow	-1.33

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.